Sanofi-Aventis: relapsing-MS drug meets endpoint – MarketWatch

Sanofi-Aventis: relapsing-MS drug meets endpointMarketWatchTEL AVIV (MarketWatch) — Sanofi-Aventis SA (NYSE:SNY) (EURONEXT:FR:SAN) , the Paris health-care group, said Monday that teriflunomide, a once-daily …Teriflunomide Significantly Reduced Annualized Relapse Rate and was Well …PR Newswire (press release)all 13 news articles »